Effect of IFN-γ on Innate Immune Cells

Chronic Granulomatous Disease Clinical Trial

Official title:

Effect of Interferon-gamma 1-b on Innate Immune Cells

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02609932
• Other study ID #: 15-1643
• Secondary ID: UL1TR001082
• Status: Completed
• Phase: Phase 1
• Start date: July 2016
• Est. completion date: February 2019

Study information

• Verified date: February 2019
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators hypothesize that neutrophils and monocytes developed under the influence of Interferon- gamma-1b (IFN-γ-1b, Actimmune*) in vivo will display enhanced function across a broad range of activities related in large part to the transcriptional activation effects of this cytokine. The investigators will evaluate the effects of IFN-γ in healthy human subjects in vivo on gene expression, biologic activity markers, and functional activity of myeloid cells in single dose studies and in steady state studies.

Description:

Named for their potent ability to interfere and protect against viral infections, interferons (IFNs) have many regulatory effects on the immune system.1 Of the members of the two classes of these compounds, IFN-γ has the most diverse and powerful immune effects. Studies have mostly evaluated IFN-γ interactions with cells of adaptive immunity, including macrophages and lymphocytes. Effects on innate immunity, particularly polymorphonuclear leukocytes or neutrophils and monocytes are less well studied. However, investigations have suggested that IFN-γ may be involved in signal transduction, gene expression, the respiratory burst and neutrophil NADPH oxidase (Nox2) activity, phagocytosis, motility, microbicidal activity, and apoptosis. Not all of these functions are enhanced by IFN-γ; but the clinical use of this cytokine has been driven, in part by these results. For example, the primary motivation for initiating investigation of its beneficial clinical effects in Chronic Granulomatous Disease (CGD) was its effects on Nox2 activity.2 Most data in this area was based on studies using differentiated neutrophils from peripheral blood.1 However, the phenotype of neutrophils developed under the influence of this cytokine, not just changes expressed by exposure of differentiated cells to IFN-γ, is critical to understanding the physiologic effects of IFN-γ and the broad applications for its use in treatment of a range of human diseases. To expand their understanding of the role of IFN-γ in the development and functional integrity of the neutrophil, the investigators have completed a series of studies with PLB-985 cells in an in vitro culture system of myeloid cells. In this proposal, the investigators will evaluate innate immune activation and phagocyte function in healthy adult volunteers who are receiving IFN-γ.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 2019
• Est. primary completion date: August 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Healthy adults over the age of 18 years up to 60 years.

2. At time of screening subject is well and healthy;

3. Acute infections resolved;

4. Subject off treatment medications;

5. No diagnosis of chronic conditions or active health care issues for which the subject is actively followed by a health care provider or is on chronic medications.

6. Non-prescription medications for mild inter-current illnesses will be allowed at the discretion of the principal investigator.

Exclusion Criteria:

1. Pregnancy.

2. History of current infection;

3. Two weeks from most recent intercurrent infection;

4. History of recurrent infections or immunodeficiency.

Related Conditions & MeSH terms

• Chronic Granulomatous Disease
• Granulomatous Disease, Chronic

Intervention

Drug:
• Administration of drug (Interferon-gamma 1-b) subcutaneously
SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.

Locations

Country	Name	City	State
United States	University of Colorado Denver, Anschutz Medical Campus	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR. INF-? Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself. PLoS One. 2015 Aug 28;10(8):e0136766. doi: 10.1371/journal.pone.0136766. eCollection 2015. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Neutrophil Nox2 activity.	Nox2 activity will be measured by DHR oxidation or Sod inhibitable cytochrome c reduction.	Determine the change in Nox2 activity at baseline compared to results for 8,24,48,72,96 hours after each IFN dose for the SD cohort.
Primary	Change in Plasma IL-10 and Neuropterin concentration.	IL-10nd Neuropterin will be measured by ELISA.	Determine the change in IL-10 and neuropterin concentration at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort.
Primary	Change in Neutrophil Gene Expression Analysis.	RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay.	Determine the change in gene expression at baseline compared to 4, 8, 12, 24, 36, 48, 72, and 96 hours after each IFN dose, SD cohort.
Primary	Change in IFN concentration and detection of anti-IFN antibody	IFN levels and anti-drug antibody will be completed by standard assays.	Determine the change in IFN level at baseline compared to 4, 8, 12, and 24 hours after administration of each dose of IFN-gamma in the SD cohort. Determine the change in IFN antibody at baseline compared to day 7-10 and day 30 after IFN
Secondary	Change in Neutrophil Function studies.	Neutrophil chemotaxis, bactericidal activity,ingestion, degranulation, f-Actin expression, CD11b/18 expression, Nox2 activity to a variety of agonists.	Determine the change in neutrophil function at baseline compared to results on Day 8 after the 4th dose of IFN.
Secondary	Change in Anti-IFN antibody.	Anti-drug antibody to be determined by standard assay.	Determine the change in IFN antibody at baseline compared to results for 7-10 da. and 30 da. after IFN.
Secondary	Change in Monocyte function studies.	Monocyte chemotaxis, bactericidal activity,ingestion, Expression of monocyte specific surface determinants, CD11b/18 expression, Nox2 activity to a variety of agonists, cell content of specific proteins, and antibody dependent cellular cytotoxicity.	Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN.
Secondary	Change in Neutrophil and Monocyte Gene Expression Analysis.	RNA will be extracted and gene expression will be determined by Affimetrix Gene Chip assay.	Determine the change in monocyte function at baseline compared to results on Day 8 after the 4th dose of IFN.